NP
LLY icon

Ninepoint Partners’s Eli Lilly LLY Stock Holding History

Ninepoint Partners’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$650K Sell
605
-53
-8% -$50.7K 0.07% 91
2025
Q3 		$502K Buy
+658
New +$490K 0.07% 98
2025
Q2 		– Sell
-1,089
Closed -$899K – 97
2025
Q1 		$899K Sell
1,089
-90
-8% -$74.9K 0.15% 66
2024
Q4 		$910K Buy
1,179
+281
+31% +$233K 0.13% 71
2024
Q3 		$796K Buy
898
+789
+724% +$709K 0.09% 64
2024
Q2 		$98.7K Buy
+109
New +$87.2K 0.01% 101

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Ninepoint Partners's LLY Position: Q4 2025 in Review

Ninepoint Partners reduced its Eli Lilly (LLY) stake by 8.1% in Q4 2025, selling an estimated $50.7K and leaving 605 shares worth $650K. The position accounts for 0.07% of the portfolio, ranked #91.

Ninepoint Partners first reported a position in LLY in Q2 2024 and has held it in 6 quarters since. The position peaked at $910K in Q4 2024. 4,428 funds tracked by Wall St. Rank hold LLY as of Q4 2025.

  • Ninepoint Partners held 605 shares of Eli Lilly worth $650K as of Q4 2025.
  • Ninepoint Partners sold 53 Eli Lilly shares in Q4 2025, an estimated $50.7K.
  • Eli Lilly made up 0.07% of Ninepoint Partners's portfolio in Q4 2025, its #91 holding.
  • Ninepoint Partners first reported a position in Eli Lilly in Q2 2024 and has held it in 6 quarters since.
  • Ninepoint Partners's Eli Lilly position peaked at $910K in Q4 2024.
  • 4,428 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2025.

Based on Ninepoint Partners's 13F filing for Q4 2025, filed 17 Feb 2026.